Citadel Advisors
ALGS icon

Citadel Advisors’s Aligos Therapeutics ALGS Stock Holding History

Citadel Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12
Closed -$105 – 14162
2024
Q2 		$105 Buy
12
+4
+50% +$70 ﹤0.01% 14095
2024
Q1 		$196 Buy
+8
New +$159 ﹤0.01% 14397
2023
Q2 		– Sell
-4
Closed -$87 – 14271
2023
Q1 		$87 Hold
4
– – ﹤0.01% 14593
2022
Q4 		$95 Buy
+4
New +$101 ﹤0.01% 14764
2022
Q2 		– Sell
-640
Closed -$34K – 12790
2022
Q1 		$34K Buy
+640
New +$51.3K ﹤0.01% 13032

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's ALGS Position: Q2 2026 in Review

Citadel Advisors sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 54,311 shares — an estimated $404K sold.

Citadel Advisors first reported a position in ALGS in Q2 2021 and held it in 14 quarters. The position peaked at $483K in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Citadel Advisors reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 54,311 Aligos Therapeutics shares in Q2 2026, an estimated $404K.
  • Citadel Advisors first reported a position in Aligos Therapeutics in Q2 2021 and held it in 14 quarters.
  • Citadel Advisors's Aligos Therapeutics position peaked at $483K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.